JW 0101 + C 2101
Alternative Names: JW0101+C2101; LivaloVALatest Information Update: 26 Mar 2024
At a glance
- Originator JW Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dyslipidaemias; Hypertension
Most Recent Events
- 08 Nov 2022 JW Pharmaceutical completes a phase III trial in Hypertension and Dyslipidemias in South Korea (NCT05331014)
- 15 Nov 2021 Phase-III clinical trials in Dyslipidaemias in South Korea (PO) (NCT05331014)
- 15 Nov 2021 Phase-III clinical trials in Hypertension in South Korea (PO) (NCT05331014)